Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence.
Shukui QinHongming PanJean Frédéric BlancVéronique GrandoHo Yeong LimXin Ying ChangAurora O'BrateChristopher StrohManja Friese-HamimJoachim AlbersAndreas JohneSandrine FaivrePublished in: JCO precision oncology (2024)
amp may be an oncogenic driver in HCC that is sensitive to MET inhibitors such as tepotinib.